News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ekos Announces U.S. Enrollment Completion of the SEATTLE II Trial that Studies the Safety and Efficacy of Ultrasound Accelerated Thrombolysis for Treatment of Massive and Submassive Pulmonary Embolism


3/20/2013 10:38:08 AM

BOTHELL, Wash.--(BUSINESS WIRE)--EKOS Corporation, a privately held medical device company located in Bothell, Washington, announced today the completion of their second major trial for the treatment of pulmonary embolism (PE). The SEATTLE II study is a 150 patient single arm prospective study measuring the rapid reduction in right heart strain in a patient population with both massive and submassive PE. Robert W. Hubert, President and CEO of EKOS Corporation, cited U.S. patient statistics: “There are over 600,000 cases of PE each year alone of which upwards of 45% are considered major having significant clot in one or both pulmonary arteries. This clot burden interferes with the heart’s ability to pump blood into the lungs for oxygenation, causing enlargement of the right side of the heart. Not removing the clot burden quickly may result in permanent pulmonary hypertension or even death.”

Read at BioSpace.com


comments powered by Disqus
Ekos
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES